The creator highlights Cellectar Biosciences as a small-cap stock to watch due to positive Phase 2b clinical data and a potential accelerated FDA approval pathway.
Source Post
The creator discusses the potential of smaller healthcare companies reaching inflection points, using Celle...
Oct 12, 2026
The creator discusses the potential of smaller healthcare companies reaching inflection points, using Cellectar Biosciences as a case study for its recent clinical data and upcoming regulatory milestones.
Linked Mentions
Tickers discussed in this post
Moderna is mentioned as an example of a company that experienced a massive run following clinical breakthroughs.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.